Acumen Pharmaceuticals
ABOS
81 hedge funds and large institutions have $105M invested in Acumen Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 22 increasing their positions, 19 reducing their positions, and 22 closing their positions.
16% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 19
1% more funds holding
Funds holding: 80 → 81 (+1)
5% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 22
0.36% more ownership
Funds ownership: 72.18% → 72.54% (+0.36%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
40% less capital invested
Capital invested by funds: $176M → $105M (-$70.1M)
65% less call options, than puts
Call options by funds: $737K | Put options by funds: $2.11M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$6.27M |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$1.68M |
| 3 |
State Street
Boston,
Massachusetts
|
+$1.13M |
| 4 |
Renaissance Technologies
New York
|
+$1.08M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$738K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PHP
Parkman Healthcare Partners
Stamford,
Connecticut
|
-$2.34M |
| 2 |
LCM
Laurion Capital Management
New York
|
-$2.28M |
| 3 |
Millennium Management
New York
|
-$2.15M |
| 4 |
SSA
Schonfeld Strategic Advisors
New York
|
-$1.23M |
| 5 |
TCM
Tang Capital Management
San Diego,
California
|
-$1,000K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
CAS
101
CTC Alternative Strategies
Chicago,
Illinois
| – | -$45K | -11,100 | Closed |
|
|
IWC
102
Integrated Wealth Concepts
Waltham,
Massachusetts
| – | -$40.9K | -10,100 | Closed |
|
103
Macquarie Group
Sydney, NSW 2000,
Australia
| – | -$5 | -1,247 | Closed |
|
ABOS Hedge Fund Activity: Q2 2024 in Review
81 of the 6,924 institutional investors tracked by Wall St. Rank reported a position in Acumen Pharmaceuticals (ABOS) for Q2 2024, worth a combined $105M — down 40% from $176M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new ABOS positions and 22 closed out — a net gain of 1 holder — while 22 added to existing stakes and 19 trimmed.
The largest buyer was BlackRock, adding an estimated $6.27M. The largest seller was Parkman Healthcare Partners, exiting entirely with an estimated $2.34M sold.
- 81 institutional investors held Acumen Pharmaceuticals (ABOS) as of Q2 2024, up from 80 in Q1 2024.
- Funds reported $105M of Acumen Pharmaceuticals stock for Q2 2024, down 40% quarter-over-quarter.
- 23 funds opened new Acumen Pharmaceuticals positions in Q2 2024 and 22 closed out, a net change of +1 holder.
- The largest Acumen Pharmaceuticals buyer in Q2 2024 was BlackRock, an estimated $6.27M added.
- The largest Acumen Pharmaceuticals seller in Q2 2024 was Parkman Healthcare Partners, an estimated $2.34M sold.
Based on aggregated 13F filings for Q2 2024.